$NRXP NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof.

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
125
$NRXP NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
NRx Pharmaceuticals, Inc.
Mon, March 2, 2026 at 7:00 AM EST

Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.

Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.

Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders.

WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, PhD, as its Chief Medical Innovation Officer.

Prof. Brown, is a psychiatrist, neurologist, and neuroscientist who studies the underlying mechanisms of Transcranial Magnetic Stimulation (TMS) and translating these mechanisms into clinical optimization. He's the Medical Director of the McLean Hospital TMS Service, the Director of TMS research, and founding director of the Brain Stimulation Mechanisms Laboratory with more than $20M awarded in federal funding from the National Institute of Mental Health and the Defense Advanced Research Projects Agency. He holds an appointment with Harvard Medical School as Assistant Professor of Psychiatry and serves as the President of the Clinical TMS Society and founding Editor-in-Chief of the Transcranial Magnetic Stimulation journal.

Prof. Brown is an early pioneer in understanding the biologic effect of TMS and enhancing that biologic effect with neuroplastic medications, including D-cycloserine (under development by NRx as NRX-101). Additionally, he has been funded by the Defense Advanced Research Projects Agency to develop pathways to deploy TMS as a therapy for treating combat-related depression and PTSD in a manner that can be forward deployable and enhance force preparedness. At NRx, he will collaborate with Dr. Dennis McBride, PhD (CAPT Ret. US Navy, SES4 Ret., National Defense University and Office of the Secretary of Defense), who serves as a Director and Chief Strategy Officer of NRx Pharmaceuticals.

Recent evidence has suggested a high rate of return to duty among first responders with PTSD who are treated with ketamine, TMS, and hyperbaric oxygen. NRx has filed an Investigational New Drug application with FDA to test that combination with the addition of NRX-101 (D-cycloserine/lurasidone) in NRx’s HOPE Therapeutics clinic network.

“We are excited to have Dr. Brown bring his extraordinary scientific leadership and clinical acumen to our drug development program and especially to our focus on reversing PTSD and depression in military personnel, veterans, and first responders,” said Jonathan Javitt, MD, MPH, NRx’s Chairman and CEO.

“I am honored to join NRX at such a pivotal time in mechanistically informed neuropsychiatric therapeutics. The company brings exceptional expertise in translating scientific innovation into meaningful advances for patients,” said Prof. Joshua C. Brown, MD, PhD, Chief Medical Innovation Officer at NRX. “My focus will be to accelerate the integration of cutting-edge neuroscience, from our team at McLean and from leading collaborators worldwide, into scalable, evidence-based treatments that can transform outcomes for patients suffering from serious brain disorders. Academic–industry partnerships are essential to closing the gap between discovery and real-world impact. While the burden of depression, anxiety, PTSD, and suicide continues to rise, we are simultaneously entering an era of novel, rapid, and effective treatments.”

“NRX is uniquely mission-driven in its commitment to alleviating suffering associated with these conditions, including its pioneering work translating TMS-pharmacologic augmentation strategies into real-world care. I am proud to contribute to this shared vision and look forward to advancing therapies that meaningfully change lives.”

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not
place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 170

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 88

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 10

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 23

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 122

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 17

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 160

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

Bladex Reports Impressive Q1 Earnings with Substantial Growth

Updated Category News Views 256

Bladex Financial Performance in Q1 Banco Latinoamericano de Comercio Exterior, S.A. (NYSE: BLX), commonly referred to as Bladex, has announced strong financial outcomes for the first quarter of the year. The bank recorded a net profit of $51.7 million, equating to $1.40 per share, reflecting a year-over-year increase of 1%. This impressive result has contributed to an...

Continue Reading
Opportunities Open Up at Linnet Corner for Seniors

Updated Category News Views 426

Exciting Housing Opportunities for Seniors The Housing Authority of the City of Alameda (AHA) is thrilled to announce the opening of a housing wait list for its newest community, Linnet Corner. Designed specifically for seniors aged 62 and older, this community will offer modern living options in a prime location. With proper access to public transportation, grocery...

Continue Reading
Vistra Corp's Future: Sustaining Growth and Performance

Updated Category News Views 426

Vistra Corp: A Look Ahead at Potential Growth in 2025 Vistra Energy Corp (NYSE: VST) has gained significant attention among investors due to its impressive performance. The company's stock experienced a remarkable 260% increase in value, cementing its position as the second-best performer in its sector. As we begin 2025, Vistra has already displayed positive momentum with...

Continue Reading
Relive Health's New Coral Gables Center Promotes Wellness

Updated Category News Views 346

Relive Health's New Coral Gables Location Set to Energize Wellness Relive Health is excited to announce the grand opening of its latest wellness center in Coral Gables. This expansion reflects the company's commitment to enhancing the health and vitality of communities through cutting-edge wellness solutions. A Comprehensive Wellness Experience This new clinic offers a...

Continue Reading
EssilorLuxottica and Meta Unveil Next-Gen AI Glasses in 2025

Updated Category News Views 456

Exciting Innovations in Wearable Technology EssilorLuxottica and Meta Platforms, Inc. have unveiled their latest advancements in the realm of AI glasses at the recent Meta Connect event. Building on their successful collaboration, these two industry leaders are set to redefine how consumers interact with technology through innovative wearables. The newest models,...

Continue Reading